LMP1 promotes nasal NK/T-cell lymphoma cell function by eIF4E via NF-κB pathway

Sun,Lu; Zhao,Yu; Shi,Huaiyin; Ma,Chao; Wei,Lixin

doi:10.3892/or.2015.4305

LMP1 promotes nasal NK/T-cell lymphoma cell function by eIF4E via NF-κB pathway

Authors:
- Lu Sun
- Yu Zhao
- Huaiyin Shi
- Chao Ma
- Lixin Wei
View Affiliations

Affiliations: Department of Pathology, Hainan Branch of PLA General Hospital, Sanya 572000, P.R. China, Department of Hematology, PLA General Hospital, Beijing 100853, P.R. China, Department of Pathology, PLA General Hospital, Beijing 100853, P.R. China
Published online on: September 23, 2015 https://doi.org/10.3892/or.2015.4305
Pages: 3264-3271

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasal natural killer T-cell lymphoma (NKTL) is a highly malignant tumor that is closely associated with Epstein-Barr virus (EBV) infection. Latent membrane protein 1 (LMP1) is encoded by EBV and plays an important role in EBV-induced cell transformation. Therefore, we assessed the function of LMP1 as a stimulant of NKTL progression and the underlying mechanism. A human EBV-positive NKTL cell line (SNK-6) was transfected with pcDNA3.1-LMP1, LV-LMP1 shRNA or LV-eukaryotic translation initiation factor 4E (eIF4E)-shRNA. Then, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was used to assess the proliferation of SNK-6 cells, and cell migration and invasion were analyzed by transwell chamber assay. Flow cytometry was used to analyze the cell cycle and apoptosis. The results showed LMP1 was highly expressed in SNK-6 cells compared with control groups. Following pretreatment with LMP1 shRNA, the proliferation of SNK-6 cells was inhibited and resulted in a G0/G1 phase arrest. A reduction in invasion and migration was also observed. LMP1 silencing promoted cell apoptosis. Further mechanistic analysis suggested that LMP1 overexpression induced the expression of eIF4E, while eIF4E-shRNA dramatically attenuated the increase in cell proliferation, invasion, migration and the inhibition of apoptosis triggered by LMP-1 upregulation. Moreover, the effect of LMP1 on eIF4E expression was mediated by the NF-κB pathway. Therefore, this finding may provide a potential target against NKTL.

View Figures

View References

1	Vose J, Armitage J and Weisenburger D; International T-Cell Lymphoma Project: International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
2	Au W-Y, Ma S-Y, Chim C-S, Choy C, Loong F, Lie AK, Lam CC, Leung AY, Tse E, Yau CC, et al: Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: A single center experience of 10 years. Ann Oncol. 16:206–214. 2005. View Article : Google Scholar : PubMed/NCBI
3	No authors listed. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 89:3909–3918. 1997.PubMed/NCBI
4	Takahashi E, Ohshima K, Kimura H, Hara K, Suzuki R, Kawa K, Eimoto T and Nakamura S; NK-cell Tumor Study Group: Clinicopathological analysis of the age-related differences in patients with Epstein-Barr virus (EBV)-associated extranasal natural killer (NK)/T-cell lymphoma with reference to the relationship with aggressive NK cell leukaemia and chronic active EBV infection-associated lymphoproliferative disorders. Histopathology. 59:660–671. 2011. View Article : Google Scholar : PubMed/NCBI
5	Carbone A, Gloghini A and Dotti G: EBV-associated lymphoproliferative disorders: Classification and treatment. Oncologist. 13:577–585. 2008. View Article : Google Scholar : PubMed/NCBI
6	Cohen JI, Bollard CM, Khanna R and Pittaluga S: Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma. 49(Suppl 1): 27–34. 2008. View Article : Google Scholar : PubMed/NCBI
7	Kohrt H and Advani R: Extranodal natural killer/T-cell lymphoma: Current concepts in biology and treatment. Leuk Lymphoma. 50:1773–1784. 2009. View Article : Google Scholar : PubMed/NCBI
8	Raab-Traub N: Epstein-Barr virus transforming proteins: biologic properties and contribution to oncogenesis. DNA Tumor Viruses. Springer; pp. 259–284. 2009, View Article : Google Scholar
9	Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong AL, Lehman TA, Seddon MB, Lin Z, et al: Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: Implications for possible immune adjuvant therapy. PLoS Pathog. 9:e10033412013. View Article : Google Scholar : PubMed/NCBI
10	van Beek J, Zur Hausen A, Klein Kranenbarg E, van de Velde CJ, Middeldorp JM, van den Brule AJ, Meijer CJ and Bloemena E: EBV-positive gastric adenocarcinomas: A distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol. 22:664–670. 2004. View Article : Google Scholar : PubMed/NCBI
11	Yang YY, Koh LW, Tsai JH, Tsai CH, Wong EF, Lin SJ and Yang CC: Correlation of viral factors with cervical cancer in Taiwan. J Microbiol Immunol Infect. 37:282–287. 2004.PubMed/NCBI
12	Whitaker NJ, Glenn WK, Sahrudin A, Orde MM, Delprado W and Lawson JS: Human papillomavirus and Epstein-Barr virus in prostate cancer: Koilocytes indicate potential oncogenic influences of human papillomavirus in prostate cancer. Prostate. 73:236–241. 2013. View Article : Google Scholar
13	Cao Y: Epstein-Barr virus encoded LMP1 regulates cyclin D1 promoter activity by nuclear EGFR and STAT3 in CNE1 cells. J Exp Clin Cancer Res. 14:192013.
14	Ho CH, Chen CL, Li WY and Chen CJ: Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis. 30:1443–1451. 2009. View Article : Google Scholar : PubMed/NCBI
15	Chen R, Zhang D, Mao Y, Zhu J, Ming H, Wen J, Ma J, Cao Q, Lin H, Tang Q, et al: A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo. Mol Cancer Ther. 11:594–603. 2012. View Article : Google Scholar
16	Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF and Kieff E: Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol. 72:7900–7908. 1998.PubMed/NCBI
17	Shair KH, Bendt KM, Edwards RH, Nielsen JN, Moore DT and Raab-Traub N: Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) and LMP2A function cooperatively to promote carcinoma development in a mouse carcinogenesis model. J Virol. 86:5352–5365. 2012. View Article : Google Scholar : PubMed/NCBI
18	Yang CF, Peng LX, Huang TJ, Yang GD, Chu QQ, Liang YY, Cao X, Xie P, Zheng LS, Huang HB, et al: Cancer stem-like cell characteristics induced by EB virus-encoded LMP1 contribute to radioresistance in nasopharyngeal carcinoma by suppressing the p53-mediated apoptosis pathway. Cancer Lett. 344:260–271. 2014. View Article : Google Scholar
19	Aozasa K and Zaki MA: Epidemiology and pathogenesis of nasal NK/T-cell lymphoma: A mini-review. Sci World J. 11:422–428. 2011. View Article : Google Scholar
20	Zheng H, Li LL, Hu DS, Deng XY and Cao Y: Role of Epstein-Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell Mol Immunol. 4:185–196. 2007.PubMed/NCBI
21	Shatsky IN, Dmitriev SE, Andreev DE and Terenin IM: Transcriptome-wide studies uncover the diversity of modes of mRNA recruitment to eukaryotic ribosomes. Crit Rev Biochem Mol Biol. 49:164–177. 2014. View Article : Google Scholar : PubMed/NCBI
22	Fischer PM: Cap in hand: Targeting eIF4E. Cell Cycle. 8:2535–2541. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zhang X, Zeng J, Zhou M, Li B, Zhang Y, Huang T, Wang L, Jia J and Chen C: The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer. 11:562012. View Article : Google Scholar : PubMed/NCBI
24	De Benedetti A and Harris AL: eIF4E expression in tumors: Its possible role in progression of malignancies. Int J Biochem Cell Biol. 31:59–72. 1999. View Article : Google Scholar : PubMed/NCBI
25	De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene. 23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
26	Nasr Z, Robert F, Porco JA Jr, Muller WJ and Pelletier J: eIF4F suppression in breast cancer affects maintenance and progression. Oncogene. 32:861–871. 2013. View Article : Google Scholar
27	Oridate N, Kim HJ, Xu X and Lotan R: Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin. Cancer Biol Ther. 4:318–323. 2005. View Article : Google Scholar : PubMed/NCBI
28	DeFatta RJ, Nathan CO and De Benedetti A: Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope. 110:928–933. 2000. View Article : Google Scholar : PubMed/NCBI
29	Thornburg NJ, Kulwichit W, Edwards RH, Shair KH, Bendt KM and Raab-Traub N: LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice. Oncogene. 25:288–297. 2006.
30	Hariri F, Arguello M, Volpon L, Culjkovic-Kraljacic B, Nielsen TH, Hiscott J, Mann KK and Borden KL: The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-kappaB and is aberrantly regulated in acute myeloid leukemia. Leukemia. 27:2047–2055. 2013. View Article : Google Scholar : PubMed/NCBI